COVID-19：铜和 N-乙酰半胱氨酸（NAC）在联合使用候选抗病毒药物治疗 SARS-CoV-2 中的潜在作用。
COVID-19: The Potential Role of Copper and N-acetylcysteine (NAC) in a Combination of Candidate Antiviral Treatments Against SARS-CoV-2.
机构信息
Pharmaceutical Services, Ministry of Health of the Republic of Cyprus, Nicosia, Cyprus
National Organization for Medicines, Athens, Greece
出版信息
In Vivo. 2020 Jun;34(3 Suppl):1567-1588. doi: 10.21873/invivo.11946.
Abstract
BACKGROUND
On March 11, 2020, the World Health Organization (WHO) declared the outbreak of coronavirus disease (COVID-19) a pandemic. Since then, thousands of people have suffered and died, making the need for a treatment of severe acute respiratory syndrome-related coronavirus-2 (SARS-CoV-2) more crucial than ever.
MATERIALS AND METHODS
The authors carried out a search in PubMed, ClinicalTrials.gov and New England Journal of Medicine (NEJM) for COVID-19 to provide information on the most promising treatments against SARS-CoV-2.
RESULTS
Possible COVID-19 agents with promising efficacy and favorable safety profile were identified. The results support the combination of copper, N-acetylcysteine (NAC), colchicine and nitric oxide (NO) with candidate antiviral agents, remdesivir or EIDD-2801, as a treatment for patients positive for SARS-CoV-2.
CONCLUSION
The authors propose to study the effects of the combination of copper, NAC, colchicine, NO and currently used experimental antiviral agents, remdesivir or EIDD-2801, as a potential treatment scheme for SARS-COV-2.
摘要
背景
2020 年 3 月 11 日，世界卫生组织（WHO）宣布冠状病毒病（COVID-19）爆发为大流行。从那时起，成千上万的人遭受病痛折磨甚至死亡，因此，对于严重急性呼吸综合征相关冠状病毒-2（SARS-CoV-2）的治疗方法的需求比以往任何时候都更加迫切。
材料和方法
作者在 PubMed、ClinicalTrials.gov 和新英格兰医学杂志（NEJM）上搜索了 COVID-19 相关信息，以提供针对 SARS-CoV-2 最有前途的治疗方法的信息。
结果
确定了一些可能具有良好疗效和安全性的 COVID-19 候选药物。这些结果支持将铜、N-乙酰半胱氨酸（NAC）、秋水仙碱和一氧化氮（NO）与候选抗病毒药物瑞德西韦或 EIDD-2801 联合用于治疗 SARS-CoV-2 阳性患者。
结论
作者建议研究铜、NAC、秋水仙碱、NO 与目前使用的实验性抗病毒药物瑞德西韦或 EIDD-2801 联合使用的效果，作为 SARS-COV-2 的潜在治疗方案。
相似文献
1
COVID-19: The Potential Role of Copper and N-acetylcysteine (NAC) in a Combination of Candidate Antiviral Treatments Against SARS-CoV-2.COVID-19：铜和 N-乙酰半胱氨酸（NAC）在联合使用候选抗病毒药物治疗 SARS-CoV-2 中的潜在作用。
In Vivo. 2020 Jun;34(3 Suppl):1567-1588. doi: 10.21873/invivo.11946.
2
COVID-19: Rescue by transcriptional inhibition.新型冠状病毒肺炎：通过转录抑制进行挽救。
Sci Adv. 2020 Jul 1;6(27). doi: 10.1126/sciadv.abc6891. Print 2020 Jul.
3
An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 in human airway epithelial cell cultures and multiple coronaviruses in mice.一种口服生物利用度的广谱抗病毒药物可抑制人呼吸道上皮细胞培养中的 SARS-CoV-2 病毒和小鼠中的多种冠状病毒。
Sci Transl Med. 2020 Apr 29;12(541). doi: 10.1126/scitranslmed.abb5883. Epub 2020 Apr 6.
4
Uncertainty about the Efficacy of Remdesivir on COVID-19.瑞德西韦对COVID-19疗效的不确定性。
J Korean Med Sci. 2020 Jun 15;35(23):e221. doi: 10.3346/jkms.2020.35.e221.
5
Current pharmacological treatments for SARS-COV-2: A narrative review.新型冠状病毒肺炎的当前药物治疗：一篇叙述性综述。
Eur J Pharmacol. 2020 Sep 5;882:173328. doi: 10.1016/j.ejphar.2020.173328. Epub 2020 Jun 27.
6
Clinical benefit of remdesivir in rhesus macaques infected with SARS-CoV-2.瑞德西韦在感染 SARS-CoV-2 的恒河猴中的临床获益。
Nature. 2020 Sep;585(7824):273-276. doi: 10.1038/s41586-020-2423-5. Epub 2020 Jun 9.
7
Sofosbuvir terminated RNA is more resistant to SARS-CoV-2 proofreader than RNA terminated by Remdesivir.索非布韦终止的 RNA 比瑞德西韦终止的 RNA 对 SARS-CoV-2 校对酶更具耐药性。
Sci Rep. 2020 Oct 6;10(1):16577. doi: 10.1038/s41598-020-73641-9.
8
Remdesivir for the Treatment of COVID-19: A Systematic Review of the Literature.瑞德西韦治疗 COVID-19 的文献系统评价。
West J Emerg Med. 2020 May 20;21(4):737-741. doi: 10.5811/westjem.2020.5.47658.
9
A promising antiviral candidate drug for the COVID-19 pandemic: A mini-review of remdesivir.瑞德西韦：一种有前景的 COVID-19 大流行抗病毒候选药物：小型综述。
Eur J Med Chem. 2020 Sep 1;201:112527. doi: 10.1016/j.ejmech.2020.112527. Epub 2020 Jun 6.
10
Case report study of the first five COVID-19 patients treated with remdesivir in France.法国首例 5 例 COVID-19 患者接受瑞德西韦治疗的病例研究
Int J Infect Dis. 2020 Sep;98:290-293. doi: 10.1016/j.ijid.2020.06.093. Epub 2020 Jun 30.
引用本文的文献
1
Copper homeostasis dysregulation in respiratory diseases: a review of current knowledge.呼吸系统疾病中铜稳态失调：当前知识综述
Front Physiol. 2024 May 31;15:1243629. doi: 10.3389/fphys.2024.1243629. eCollection 2024.
2
Effect of Low Copper Doping on the Optical, Cytocompatible, Antibacterial, and SARS-CoV-2 Trapping Properties of Calcium Phosphate Glasses.低铜掺杂对磷酸钙玻璃的光学、细胞相容性、抗菌及新冠病毒捕获性能的影响
ACS Omega. 2023 Nov 1;8(45):42264-42274. doi: 10.1021/acsomega.3c04293. eCollection 2023 Nov 14.
3
Evaluation of the efficacy and safety of oral N-acetylcysteine in patients with COVID-19 receiving the routine antiviral and hydroxychloroquine protocol: A randomized controlled clinical trial.评价口服 N-乙酰半胱氨酸在接受常规抗病毒和羟氯喹方案治疗的 COVID-19 患者中的疗效和安全性：一项随机对照临床试验。
Immun Inflamm Dis. 2023 Nov;11(11):e1083. doi: 10.1002/iid3.1083.
4
Role of Metals on SARS-CoV-2 Infection: a Review of Recent Epidemiological Studies.金属元素在 SARS-CoV-2 感染中的作用：对近期流行病学研究的综述。
Curr Environ Health Rep. 2023 Dec;10(4):353-368. doi: 10.1007/s40572-023-00409-4. Epub 2023 Sep 4.
5
N-acetylcysteine reduces severity and mortality in COVID-19 patients: A systematic review and meta-analysis.N-乙酰半胱氨酸可降低COVID-19患者的严重程度和死亡率：一项系统评价和荟萃分析。
J Adv Vet Anim Res. 2023 Jun 30;10(2):157-168. doi: 10.5455/javar.2023.j665. eCollection 2023 Jun.
6
N-acetylcysteine as adjuvant therapy for hospitalized Covid-19 patients: A single-center prospective cohort study.N-乙酰半胱氨酸作为住院新冠肺炎患者的辅助治疗：一项单中心前瞻性队列研究。
Caspian J Intern Med. 2023 Summer;14(3):543-552. doi: 10.22088/cjim.14.3.553.
7
Structure-Based Drug Design of RdRp Inhibitors against SARS-CoV-2.基于结构的 RdRp 抑制剂对 SARS-CoV-2 的药物设计。
Top Curr Chem (Cham). 2023 Jun 15;381(5):22. doi: 10.1007/s41061-023-00432-x.
8
Copper(II) Chelates of Schiff Bases Enriched with Aliphatic Fragments: Synthesis, Crystal Structure, In Silico Studies of ADMET Properties and a Potency against a Series of SARS-CoV-2 Proteins.富含脂肪族片段的席夫碱铜（II）螯合物：合成、晶体结构、ADMET性质的计算机模拟研究以及对一系列SARS-CoV-2蛋白的活性
Pharmaceuticals (Basel). 2023 Feb 14;16(2):286. doi: 10.3390/ph16020286.
9
Antioxidant and Immune-Related Implications of Minerals in COVID-19: A Possibility for Disease Prevention and Management.矿物质在新冠病毒疾病中的抗氧化及免疫相关影响：疾病预防与管理的一种可能性
Antioxidants (Basel). 2023 May 16;12(5):1104. doi: 10.3390/antiox12051104.
10
The Problem of Home Therapy during COVID-19 Pandemic in Italy: Government Guidelines versus Freedom of Cure?意大利新冠疫情期间的家庭治疗问题：政府指导方针与治疗自由？
J Pharm Pharmacol Res. 2022 Aug 2;6(3):100-114. doi: 10.26502/fjppr.055.
本文引用的文献
1
Outcomes of Hydroxychloroquine Usage in United States Veterans Hospitalized with COVID-19.羟氯喹在美国 COVID-19 住院患者中的使用效果。
Med. 2020 Dec 18;1(1):114-127.e3. doi: 10.1016/j.medj.2020.06.001. Epub 2020 Jun 5.
2
The QT interval in patients with COVID-19 treated with hydroxychloroquine and azithromycin.接受羟氯喹和阿奇霉素治疗的新冠肺炎患者的QT间期。
Nat Med. 2020 Jun;26(6):808-809. doi: 10.1038/s41591-020-0888-2.
3
Copper - a novel stimulator of autophagy.铜——一种新型自噬刺激物。
Cell Stress. 2020 Apr 24;4(5):92-94. doi: 10.15698/cst2020.05.218.
4
COVID-19: Therapeutics and Their Toxicities.新型冠状病毒肺炎（COVID-19）：治疗药物及其毒性。
J Med Toxicol. 2020 Jul;16(3):284-294. doi: 10.1007/s13181-020-00777-5. Epub 2020 Apr 30.
5
The proximal origin of SARS-CoV-2.严重急性呼吸综合征冠状病毒2（SARS-CoV-2）的近端起源。
Nat Med. 2020 Apr;26(4):450-452. doi: 10.1038/s41591-020-0820-9.
6
Compassionate Use of Remdesivir for Patients with Severe Covid-19.瑞德西韦在治疗重症 COVID-19 患者中的同情使用。
N Engl J Med. 2020 Jun 11;382(24):2327-2336. doi: 10.1056/NEJMoa2007016. Epub 2020 Apr 10.
7
Phylogenetic network analysis of SARS-CoV-2 genomes.SARS-CoV-2 基因组的系统发育网络分析。
Proc Natl Acad Sci U S A. 2020 Apr 28;117(17):9241-9243. doi: 10.1073/pnas.2004999117. Epub 2020 Apr 8.
8
Corona (COVID-19) time musings: Our involvement in COVID-19 pathogenesis, diagnosis, treatment and vaccine planning.新冠（COVID-19）时期的思考：我们在新冠病毒致病机制、诊断、治疗及疫苗研发计划中的参与情况
Autoimmun Rev. 2020 Jun;19(6):102538. doi: 10.1016/j.autrev.2020.102538. Epub 2020 Apr 5.
9
Acute myocarditis presenting as a reverse Tako-Tsubo syndrome in a patient with SARS-CoV-2 respiratory infection.一名感染严重急性呼吸综合征冠状病毒2（SARS-CoV-2）的患者出现急性心肌炎，表现为反向Tako-Tsubo综合征。
Eur Heart J. 2020 May 14;41(19):1861-1862. doi: 10.1093/eurheartj/ehaa286.
10
An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 in human airway epithelial cell cultures and multiple coronaviruses in mice.一种口服生物利用度的广谱抗病毒药物可抑制人呼吸道上皮细胞培养中的 SARS-CoV-2 病毒和小鼠中的多种冠状病毒。
Sci Transl Med. 2020 Apr 29;12(541). doi: 10.1126/scitranslmed.abb5883. Epub 2020 Apr 6.
Zotero 插件